Cargando…
Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and (D)A7R...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240983/ https://www.ncbi.nlm.nih.gov/pubmed/28687044 http://dx.doi.org/10.1080/10717544.2017.1344334 |
_version_ | 1783715312388014080 |
---|---|
author | Zhang, Yue Zhai, Meifang Chen, Zhijiang Han, Xiaoyang Yu, Fanglin Li, Zhiping Xie, Xiangyang Han, Cuiyan Yu, Lian Yang, Yang Mei, Xingguo |
author_facet | Zhang, Yue Zhai, Meifang Chen, Zhijiang Han, Xiaoyang Yu, Fanglin Li, Zhiping Xie, Xiangyang Han, Cuiyan Yu, Lian Yang, Yang Mei, Xingguo |
author_sort | Zhang, Yue |
collection | PubMed |
description | Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and (D)A7R dual peptides-modified liposomes (abbreviated as T7/(D)A7R-LS) to efficiently co-delivery doxorubicin (DOX) and vincristine (VCR) to glioma in this study. T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma. (D)A7R is a d-peptide ligand of vascular endothelial growth factor receptor 2 (VEGFR 2) overexpressed on angiogenesis, presenting excellent glioma-homing property. By combining the dual-targeting delivery effect, the dual-modified liposomes displayed higher glioma localization than that of single ligand-modified liposomes or free drug. After loading with DOX and VCR, T7/(D)A7R-LS showed the most favorable antiglioma effect in vivo. In conclusion, this dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy. |
format | Online Article Text |
id | pubmed-8240983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-82409832021-07-08 Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma Zhang, Yue Zhai, Meifang Chen, Zhijiang Han, Xiaoyang Yu, Fanglin Li, Zhiping Xie, Xiangyang Han, Cuiyan Yu, Lian Yang, Yang Mei, Xingguo Drug Deliv Research Article Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and (D)A7R dual peptides-modified liposomes (abbreviated as T7/(D)A7R-LS) to efficiently co-delivery doxorubicin (DOX) and vincristine (VCR) to glioma in this study. T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma. (D)A7R is a d-peptide ligand of vascular endothelial growth factor receptor 2 (VEGFR 2) overexpressed on angiogenesis, presenting excellent glioma-homing property. By combining the dual-targeting delivery effect, the dual-modified liposomes displayed higher glioma localization than that of single ligand-modified liposomes or free drug. After loading with DOX and VCR, T7/(D)A7R-LS showed the most favorable antiglioma effect in vivo. In conclusion, this dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy. Taylor & Francis 2017-07-07 /pmc/articles/PMC8240983/ /pubmed/28687044 http://dx.doi.org/10.1080/10717544.2017.1344334 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhang, Yue Zhai, Meifang Chen, Zhijiang Han, Xiaoyang Yu, Fanglin Li, Zhiping Xie, Xiangyang Han, Cuiyan Yu, Lian Yang, Yang Mei, Xingguo Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma |
title | Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma |
title_full | Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma |
title_fullStr | Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma |
title_full_unstemmed | Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma |
title_short | Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma |
title_sort | dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240983/ https://www.ncbi.nlm.nih.gov/pubmed/28687044 http://dx.doi.org/10.1080/10717544.2017.1344334 |
work_keys_str_mv | AT zhangyue dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT zhaimeifang dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT chenzhijiang dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT hanxiaoyang dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT yufanglin dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT lizhiping dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT xiexiangyang dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT hancuiyan dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT yulian dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT yangyang dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma AT meixingguo dualmodifiedliposomecodeliveryofdoxorubicinandvincristineimprovetargetingandtherapeuticefficacyofglioma |